USA Financial Formulas Purchases 5,816 Shares of MetLife, Inc. $MET

by · The Markets Daily

USA Financial Formulas purchased a new position in shares of MetLife, Inc. (NYSE:MET – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,816 shares of the financial services provider’s stock, valued at approximately $548,000.

A number of other institutional investors also recently bought and sold shares of MET. Kintegral Advisory LLC boosted its stake in shares of MetLife by 0.6% during the third quarter. Kintegral Advisory LLC now owns 50,383 shares of the financial services provider’s stock worth $4,744,000 after buying an additional 284 shares during the period. TD Waterhouse Canada Inc. grew its holdings in shares of MetLife by 136.5% during the third quarter. TD Waterhouse Canada Inc. now owns 373,636 shares of the financial services provider’s stock worth $35,280,000 after buying an additional 215,666 shares during the last quarter. Pension & Wealth Management Advisors Inc. grew its holdings in shares of MetLife by 62.0% during the third quarter. Pension & Wealth Management Advisors Inc. now owns 810 shares of the financial services provider’s stock worth $76,000 after buying an additional 310 shares during the last quarter. Cantor Fitzgerald Investment Advisors L.P. grew its holdings in shares of MetLife by 2.1% during the third quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 175,989 shares of the financial services provider’s stock worth $16,571,000 after buying an additional 3,557 shares during the last quarter. Finally, V Square Quantitative Management LLC increased its position in MetLife by 0.5% in the 3rd quarter. V Square Quantitative Management LLC now owns 40,436 shares of the financial services provider’s stock valued at $3,807,000 after acquiring an additional 200 shares during the period. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on MET shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of MetLife in a research note on Friday, September 11th. Atlantic Securities set a $103.00 target price on MetLife in a research note on Wednesday, July 15th. Barclays lifted their target price on MetLife from $97.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Keefe, Bruyette & Woods boosted their target price on MetLife from $105.00 to $108.00 and gave the company an “outperform” rating in a report on Tuesday, August 11th. Finally, Wells Fargo & Company upped their price target on MetLife from $109.00 to $110.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Thirteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, MetLife currently has an average rating of “Moderate Buy” and an average target price of $105.19.

Read Our Latest Research Report on MET

MetLife News Summary

Here are the key news stories impacting MetLife this week:

  • Positive Sentiment: JPMorgan raised its price target for MetLife from $108 to $110 and maintained an “overweight” rating. The new target implies approximately 9% upside from the referenced share price, signaling continued confidence in MetLife’s earnings outlook and valuation.
  • Positive Sentiment: Dowling & Partners increased its FY2026 EPS forecast to $10.30 from $10.10. The revised estimate is also above the broader consensus forecast of $9.90, suggesting expectations for stronger profitability. MetLife Hits New 52-Week High on Analyst Upgrade
  • Positive Sentiment: MetLife reached a new 52-week high following an analyst upgrade. The move reflects sustained investor demand and momentum around the insurer’s earnings performance and analyst outlook. MetLife Hits New 52-Week High on Analyst Upgrade
  • Positive Sentiment: Brokerages’ consensus price target is reported at $105.06, providing additional evidence that analysts see potential upside for MET. MetLife Consensus Price Target
  • Neutral Sentiment: MetLife Foundation awarded a $1 million grant to Ascendus for its Get Ready program. The initiative supports financial preparedness and may enhance MetLife’s corporate reputation, but it is unlikely to materially affect near-term earnings. Ascendus Expands Get Ready Program
  • Neutral Sentiment: Articles about concerts, NFL venues and events at MetLife Stadium concern the stadium’s entertainment operations, not MetLife, Inc.’s insurance and financial-services business, so they are not expected to influence MET materially.

MetLife Stock Up 0.5%

Shares of NYSE:MET opened at $100.73 on Friday. The company has a market cap of $64.82 billion, a price-to-earnings ratio of 19.30, a PEG ratio of 0.95 and a beta of 0.78. The firm’s 50-day simple moving average is $96.87 and its 200-day simple moving average is $88.73. The company has a quick ratio of 0.20, a current ratio of 0.20 and a debt-to-equity ratio of 0.52. MetLife, Inc. has a fifty-two week low of $67.33 and a fifty-two week high of $102.43.

MetLife (NYSE:MET – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The financial services provider reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.13. The business had revenue of $13.52 billion for the quarter, compared to analyst estimates of $19.67 billion. MetLife had a net margin of 4.57% and a return on equity of 23.39%. The business’s revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the business posted $2.02 earnings per share. As a group, equities research analysts predict that MetLife, Inc. will post 9.93 earnings per share for the current year.

MetLife Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 3rd will be issued a $0.5925 dividend. This represents a $2.37 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, November 3rd. MetLife’s payout ratio is currently 45.40%.

MetLife declared that its Board of Directors has initiated a share repurchase program on Wednesday, August 5th that allows the company to repurchase $3.00 billion in shares. This buyback authorization allows the financial services provider to buy up to 4.8% of its stock through open market purchases. Share buyback programs are often an indication that the company’s management believes its stock is undervalued.

MetLife Profile

(Free Report)

MetLife, Inc (NYSE: MET) is a global financial services company that provides insurance, retirement, and employee benefits solutions to individuals, employers, and institutions. Its offerings include life insurance, dental and vision coverage, accident and disability insurance, annuities, retirement savings products, and related financial services.

Through its institutional and workplace businesses, MetLife helps employers provide benefits and retirement programs to their employees. The company also serves individual customers with protection and income products.

Recommended Stories